mRNA-based Cancer Vaccine Development Solutions

Q: How does mRNA differ from DNA vaccines in terms of delivery?

mRNA only needs to reach the cytoplasm to be translated, whereas DNA vaccines must cross the nuclear membrane to be transcribed. This makes mRNA inherently more efficient for non-dividing cells and eliminates the need for aggressive delivery methods like electroporation, although LNP encapsulation is typically required for mRNA stability.

Q: Why do you recommend using modified nucleosides like N1-methylpseudouridine?

Unmodified mRNA is recognized by innate immune sensors (TLR7/8, PKR), which can shut down protein translation and cause inflammation. Incorporating modified nucleosides allows the mRNA to evade these sensors ('stealth mode'), resulting in significantly higher antigen expression and better tolerability.

Q: Can you target the mRNA vaccine to present antigens via MHC Class II?

Yes. Naturally, cytosolic mRNA translation feeds mainly into the MHC Class I pathway. To enhance CD4+ T cell help, we can fuse the antigen sequence with lysosomal trafficking signals (e.g., LAMP-1), directing the protein to the endosome/lysosome for processing and loading onto MHC Class II molecules.

Q: What is the advantage of your microfluidic LNP assembly?

Microfluidic mixing provides precise control over the mixing rate of lipids and mRNA, resulting in LNPs with a very narrow size distribution (low Polydispersity Index) and high encapsulation efficiency (>90%). This reproducibility is critical for obtaining consistent data in preclinical studies.

Messenger RNA (mRNA) has revolutionized vaccine development, serving as a non-infectious, non-integrating platform that enables transient yet potent expression of tumor antigens. By harnessing the host's cytosolic machinery, mRNA vaccines can drive robust CD8+ T-cell responses essential for tumor elimination.

Creative Biolabs offers an integrated mRNA cancer vaccine development solution focused on precision engineering. From computational codon optimization and modified nucleoside incorporation to advanced Lipid Nanoparticle (LNP) formulation, we overcome the traditional hurdles of stability and immunogenicity to accelerate your preclinical research.

Get a Quote

Overcoming Hurdles in mRNA Therapeutics

While mRNA offers superior safety profiles compared to DNA or viral vectors, its successful application relies on solving critical stability and delivery challenges:

▶ Innate Immune Activation: Unmodified mRNA can trigger PKR and TLRs, leading to translation arrest. We employ Modified Nucleosides (e.g., N1-methylpseudouridine) to suppress this response and enhance protein yield.
▶ Intracellular Delivery: Naked mRNA is rapidly degraded by RNases. Our LNP Encapsulation Platform ensures protection and efficient endosomal escape.
▶ Antigen Presentation Balance: While cytosolic delivery favors MHC I, MHC II presentation is crucial for CD4+ help. We engineer Trafficking Signals (e.g., LAMP-1 fusion) to route antigens to lysosomal compartments.
▶ Translational Efficiency: Suboptimal sequences limit expression. Our AI-driven Codon Optimization maximizes ribosome occupancy and mRNA half-life.

Consult Our Experts

Our Solutions

We provide a complete "Sequence-to-Vial" service ecosystem, ensuring every component of the mRNA vaccine is optimized for oncology applications:

Sequence Engineering

Design of 5' and 3' UTRs, Poly(A) tail length optimization, and inclusion of signal peptides (e.g., tissue plasminogen activator) to boost secretion or presentation.

High-Quality IVT Synthesis

Scalable In Vitro Transcription (IVT) using modified nucleotides (5mC, Ψ, m1Ψ) and Cap 1 analogues to ensure low immunogenicity and high capping efficiency.

Advanced LNP Formulation

Microfluidic assembly of Lipid Nanoparticles using proprietary ionizable lipids (e.g., DLin-MC3-DMA analogs), optimizing N/P ratios for maximum encapsulation efficiency (>90%).

Immune Profiling

Comprehensive evaluation of innate immune activation (cytokine release) and adaptive responses (Tetramer staining, ELISpot) in preclinical models.

Specialized mRNA Platforms

Creative Biolabs offers diverse mRNA architectures and modification strategies tailored to specific tumor antigen types:

Modified Nucleoside mRNA Synthesis

We provide custom synthesis of mRNA incorporating naturally occurring modified nucleosides such as Pseudouridine (Ψ), N1-methylpseudouridine (m1Ψ), and 5-methylcytidine (5mC). These modifications are critical for suppressing PKR activation, reducing interferon signaling, and enhancing translational capacity.

Learn More →

Self-Replicating RNA (saRNA) Vaccines

Derived from alphavirus vectors (e.g., VEEV, SINV), our saRNA platform encodes the antigen of interest alongside viral replicase genes. This enables intracellular amplification of the RNA, resulting in higher antigen expression from lower doses compared to conventional mRNA.

Learn More →

LNP Formulation & Characterization

Our service includes the rapid screening of cationic lipids (DOTMA, DOTAP, MC3) and helper lipids to optimize tissue targeting. We perform rigorous physicochemical characterization including particle size (DLS), Zeta potential, and encapsulation efficiency (Ribogreen assay).

Learn More →

MHC Trafficking Signal Engineering

To overcome the bias of mRNA vaccines towards MHC Class I presentation, we fuse antigens with sorting signals such as LAMP-1 (lysosomal associated membrane protein) or DC-LAMP. This directs the protein to the endosomal/lysosomal compartment for enhanced MHC Class II loading and CD4+ T cell activation.

Learn More →

Neoantigen mRNA Vaccine Customization

Combining our AI-based neoantigen prediction platform with mRNA technology, we design personalized vaccines encoding up to 20 patient-specific neoepitopes in a single strand (concatemer), connected by optimized linkers for efficient proteasomal processing.

Learn More →

Streamlined Development Workflow

Our integrated pipeline moves from computational design to LNP encapsulation and validation with high efficiency:

Step 1: In Silico Design & Template Generation

Service: Computational codon optimization for human tRNA abundance, secondary structure minimization, and plasmid template linearization. Design of UTRs for maximum stability.

Step 2: IVT Synthesis & Capping

Service: T7 RNA polymerase-mediated transcription using N1-methylpseudouridine. Co-transcriptional capping to generate functional Cap 1 structures with high efficiency (>95%).

Step 3: Purification & QC

Service: Removal of dsRNA contaminants via cellulose purification or HPLC to prevent unwanted innate immune activation. QC includes capillary electrophoresis (fragment analyzer) for integrity and endotoxin testing.

Step 4: Microfluidic LNP Encapsulation

Service: Rapid mixing of mRNA (aqueous phase) and lipids (ethanol phase) using microfluidic devices to form uniform LNPs with controlled size (typically 60-100 nm) and low polydispersity (PDI < 0.2).

Step 5: In Vivo Immunogenicity Study

Service: Intramuscular injection in mice. Evaluation of antigen expression (Luciferase reporter), T-cell priming (ELISpot, ICS), and antitumor efficacy in syngeneic tumor models.

Note: This workflow is strictly for preclinical research and development purposes.

Start Your Project

Advanced Technology Platforms

Our mRNA vaccine solutions are powered by proprietary technologies designed for stability and translation:

A specialized platform for the rapid production of high-quality mRNA. We utilize proprietary vectors with optimized T7 promoters and UTR sequences. Our enzymatic capping (Vaccinia Capping Enzyme) or co-transcriptional capping options ensure high translation initiation rates.

Poly(A) tail length control (100-150 nt)
dsRNA removal protocols

State-of-the-art microfluidic mixing technology enabling the reproducible production of Lipid Nanoparticles. This platform allows for the precise tuning of N/P ratios (Nitrogen to Phosphate) and lipid composition to maximize cellular uptake.

Scalable from µg to mg
Consistent particle size control
Screening of novel ionizable lipids

A suite of modified nucleotides available for incorporation during IVT. By replacing Uridine with N1-methylpseudouridine or 5-methoxyuridine, we drastically reduce TLR7/8 sensing, thereby preventing translational shutdown by PKR/OAS pathways.

N1-methylpseudouridine (m1Ψ)
5-methylcytidine (5mC)
Codon optimization algorithms

Advanced assays to assess the potency of mRNA vaccines. We use reporter assays (eGFP, Fluc) to quantify protein expression kinetics in vitro and flow cytometry to measure dendritic cell maturation and antigen presentation.

Reporter gene assays
Western Blot verification
Intracellular Cytokine Staining (ICS)

High-Yield IVT System

Microfluidic LNP Assembly

Nucleoside Modification

Potency Evaluation

Inquire About Our Technology

Why Choose Creative Biolabs

Superior Safety Profile

Non-infectious, non-integrating mRNA platform eliminates the risk of genomic mutagenesis.

Rapid Development

Cell-free production process allows for vaccine candidate generation in weeks, not months.

Versatile Delivery

Expertise in both standard LNPs and novel polymeric carriers for targeted delivery.

Dual-Pathway Activation

Engineered sequences capable of stimulating both CD8+ (MHC I) and CD4+ (MHC II) T-cell responses.

Request a Free Consultation

Frequently Asked Questions

Q: How does mRNA differ from DNA vaccines in terms of delivery?

A: mRNA only needs to reach the cytoplasm to be translated, whereas DNA vaccines must cross the nuclear membrane to be transcribed. This makes mRNA inherently more efficient for non-dividing cells and eliminates the need for aggressive delivery methods like electroporation, although LNP encapsulation is typically required for mRNA stability.

Q: Why do you recommend using modified nucleosides like N1-methylpseudouridine?

A: Unmodified mRNA is recognized by innate immune sensors (TLR7/8, PKR), which can shut down protein translation and cause inflammation. Incorporating modified nucleosides allows the mRNA to evade these sensors ("stealth mode"), resulting in significantly higher antigen expression and better tolerability.

Q: Can you target the mRNA vaccine to present antigens via MHC Class II?

A: Yes. Naturally, cytosolic mRNA translation feeds mainly into the MHC Class I pathway. To enhance CD4+ T cell help, we can fuse the antigen sequence with lysosomal trafficking signals (e.g., LAMP-1), directing the protein to the endosome/lysosome for processing and loading onto MHC Class II molecules.

Q: What is the advantage of your microfluidic LNP assembly?

A: Microfluidic mixing provides precise control over the mixing rate of lipids and mRNA, resulting in LNPs with a very narrow size distribution (low Polydispersity Index) and high encapsulation efficiency (>90%). This reproducibility is critical for obtaining consistent data in preclinical studies.

Q: What is the typical turnaround time for a custom mRNA vaccine batch?

A: For research-grade mRNA (from gene synthesis to purified mRNA), the process typically takes 2-4 weeks. If LNP encapsulation and characterization are required, please allow an additional 1-2 weeks. We also offer expedited services for urgent projects.

Ask Our Experts

Related Resources